Equity
€1.9m ▲ 1.0%
PHARMALEX has made a profit in every financial year since 2006.
PHARMALEX
Part of the group
10 companies in 2 countries
Lifetime
20 annual accounts with figures on one time axis, 25 filings since 2001peak €1.5m (2021)
€1.2m▼ 4.9%
peak €705,655 (2021)
€64,882▼ 62.7%
peak €2.0m (2020)
€1.9m▲ 1.0%
€356,010▼ 43.2%
peak 16.1 FTE (2013)
15 FTE▲ 1.4%
Board4 names since 2022
3 directors and 2 others
Owners2 names in the annual accounts
100% and 1 other
Documentsfilings and deeds
08-01-202623 days before the deadline
2025financial year
Result from €174,155 to €64,882Debts from €626,802 to €356,010Cash from €322,352 to €431,662
Key points
from the 2025 annual accountsResult
€64,882 ▼ 62.7%
The result fell in 2025 from €174,155 to €64,882.
Staff
16 employees on 30-06-2025
In 2025, 3 people joined and 3 left.
Filings
25 annual accounts 26 filings since 2001
The 2023 accounts came 85 days late. The other nine of the last ten were filed on time.
Board
1 joined · 2 left
Board changed. Latest change 03-08-2026 · 1 in office.
Position in the sector
84.3%
Higher solvency than 89% of companies in legal and accounting. Sector median 26.7% · 806 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 14,769 companies had the same profile as PHARMALEX has now. Each dot stands for 37 companies, two years later.
96.2%
were still trading
3.5%
stopped another way
0.2%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 14,769 companies, not a prediction for PHARMALEX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, , since 01-11-2025
Auditor,
- 100%equity €1.1m (2025) · 30-06-2025 annual accounts of
- consolidatesannual accounts 30-06-2025
Recent changes
1 director appointed, 2 resignations, 1 statutory auditor reappointed
Resignations: and · Appointment: (director) · Permanent representative: · Board meeting of 01-07-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0471925883
Appointment: (statutory auditor)
Permanent representative: · General meeting of 22-09-2022 · Gazette deed
Changes of role: (director) and (director)
“Les services juridiques en rapport avec les activités du professionnel; Fournir des conseils,des consultations…” (deed in French) · General meeting of 20-06-2022 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMALEX Liège | €2.3m | €1.2m | 84.3% | 15 |
| ACCOUNTANCY KAVA Antwerp | €2.3m | €1.4m | 70.2% | 14.1 |
| FIDUCIAIRE HUPPERETZ & CIE Malmedy | €2.0m | €1.5m | 38.1% | 13.6 |
| Fiduciaire Montgomery Watermael-Boitsfort | €2.6m | €1.1m | 18.5% | 12.7 |
| AXENTIS Maaseik | €2.0m | €1.4m | 32.4% | 14.8 |
| Groupe MDS Jette | €1.8m | €1.2m | 58.6% | 12.8 |
| FISCAAL CONSULT Geraardsbergen | €2.1m | €1.5m | 58.9% | 14.8 |
These companies have the same main activity as PHARMALEX: certified accountants and tax accountants (NACE 69201). They are comparable in size and age: total assets between €1.8m and €2.6m, founded between 1991 and 2003.
Official details
Source: KBO- Status
- Active since 19-05-2000Normal situation
- Registered office
- 11 active companies are registered at this addressSource: KBO register, as of 12 November 2026.
- Activity
- Certified accountants and tax accountantsNACE 69201
- Joint committee
- 336Liberal professions · annual accounts 30-06-2025
- Establishment unit
- 2.229.125.0294020 Liège, since 17-05-2000
- Financial year end
- 30 June
- Peppol
- Reachable since 31-10-2025
Annual accounts to 30-06-2025
- ≈ €2.0mestimated
- €2.3m▼ 10.0%
- Employeeson 30-06-2025
- 16=
- Filing
- Filed on 08-01-2026, 23 days before the end of the filing period
Insights on PHARMALEX
PHARMALEX has existed since 2000. The gross margin fell from €1.5m in 2021 to €595,958 in 2022.
Solvency rose in 2025 from 75.2% to 84.3% because of the retained profit and lower debts.
holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMALEX
- What is the company number of PHARMALEX?
- The company number of PHARMALEX is 0471.925.883. The VAT number is the same number with BE in front: BE 0471.925.883.
- Where is PHARMALEX based?
- The registered office is at Rue de Mulhouse 33, 4020 Liège.Company details
- What does PHARMALEX do?
- According to the KBO register, the main activity is certified accountants and tax accountants (NACE 69201).
- What is the legal form of PHARMALEX?
- PHARMALEX is a private limited company (BV).
- When was PHARMALEX founded?
- PHARMALEX was founded on 19-05-2000.
- Is PHARMALEX still active?
- Yes, PHARMALEX is an active enterprise in the KBO register.
- How many employees does PHARMALEX have?
- PHARMALEX had an average of 15 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does PHARMALEX fall under?
- In its 30-06-2025 annual accounts, PHARMALEX states joint committee 336 (Liberal professions).
- What is the turnover of PHARMALEX?
- The turnover in financial year 2025 is ≈ €2.0m. This figure is estimated from the gross margin of €1.2m and 1,585 comparable companies of the same size. It probably lies between €1.3m and €3.3m. It is a rough estimate. In financial year 2023 turnover was €1.9m.
- Is PHARMALEX profitable?
- In financial year 2025, PHARMALEX made a profit of €64,882.
- Where can I find the annual accounts of PHARMALEX?
- PHARMALEX filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMALEX due?
- PHARMALEX must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.